PIK3CA E545K (Q28371031)

From Wikidata

Jump to navigation Jump to search

genetic variant

GLU545LYS
E545K
RS104886003

Language	Label	Description	Also known as
English	PIK3CA E545K	genetic variant	GLU545LYS E545K RS104886003

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

human chromosome 3

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

178936091

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

178936091

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

positive therapeutic predictor for

medical condition treated

determination method

CIViC evidence level C

CIViC 1-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1550

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

pictilisib / cisplatin combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

cervix carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2984

Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2034

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2062

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

negative therapeutic predictor for

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1171

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/387

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/387

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

statement disputed by

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2037

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

statement disputed by

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2037

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3722

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

ado-trastuzumab emtansine

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

statement disputed by

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2036

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2217

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Trastuzumab / Lapatinib combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6211

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1670

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1670

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

cervix uterine cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2985

Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells

negative prognostic predictor for

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2106

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_006218.3:c.1633G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

NP_006209.2:p.Glu545Lys

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

ENST00000263967.3:c.1633G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

NC_000003.11:g.178936091G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371031&oldid=2014798369"